TheraRadar
← Back
Data updated: Jun 28, 2026

TREVENA

Pharma
CardiovascularNeurology Execution: Excellent

TREVENA is a pharmaceutical company focused on Cardiovascular, Neurology. Key products include OLINVYK.

2020
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

FDA Novel Drug Designations

(2020)
1 Novel 1 Fast Track
See 1 novel approval →
2020 OLINVYK (OLICERIDINE) Fast Track

TREVENA at a Glance

  • Strong track record with 90% execution quality across 16 trials
  • Fast trial execution (8 months median completion)

TREVENA's Key Drugs

TREVENA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

TREVENA's Recent FDA Approvals

New NDA/BLA approvals for TREVENA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

TREVENA's Therapeutic Areas

TREVENA's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 80%
0 drugs Phase 2: 1 Phase 1: 2
Neurology 20%
0 drugs Phase 1: 1

TREVENA's Top Competitors

TREVENA's closest competitors by therapeutic-area and drug-target overlap include GE HEALTHCARE, Novo Nordisk, and LEDERLE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

GE HEALTHCARE specialty
Neurology, Cardiovascular
Novo Nordisk big-pharma
Cardiovascular, Neurology
LEDERLE big-pharma
Cardiovascular, Neurology
AZURITY specialty
Cardiovascular, Neurology
PAI HOLDINGS PHARM specialty
Neurology, Cardiovascular

TREVENA Pipeline Snapshot

TREVENA has 4 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 3 Phase 1.

0
Phase 3
1
Phase 2
3
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Cardiovascular pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 3/3 completed
  • • Speed: 8 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges